Why the study?
Percutaneous left atrial appendage closure carries risks of silent brain infarcts that can lead to cognitive impairment, and whether mechanical neuroprotection during the procedure reduces this risk is unknown.
Does the Sentinel CPS reduce the number of new silent brain infarcts detected by DW MRI in patients with atrial fibrillation undergoing LAAC?
Does the Sentinel CPS reduce the number of new silent brain infarcts detected by DW MRI in patients with atrial fibrillation undergoing LAAC?
The LAAC-SBI trial will evaluate whether mechanical neuroprotection during left atrial appendage closure reduces silent brain infarcts and preserves cognitive function.
Answers are grounded in this paper and cite their sources.
Mechanical neuroprotection during LAAC may reduce SBI; supports larger RCTs assessing cognitive and clinical outcomes.
Background: Left atrial appendage closure (LAAC) procedures prevent cardioembolic stroke in patients with atrial fibrillation who have contraindications to oral anticoagulant medications. However, these procedures carry certain risks of peri-procedural complications. One such complication is silent brain infarcts (SBI), which can lead to cognitive impairment and mood disturbances. The implementation of mechanical neuroprotection systems during LAAC procedures may reduce the risk of SBI and associated cognitive and mood disorders. Methods: The LAAC-SBI trial is a prospective, multicenter, randomized, and double-blind interventional study. The study aims to enroll a total of 240 patients, with 120 patients allocated to each group. The study group will evaluate the use of the Sentinel CPS during LAAC, while the control group will undergo LAAC procedures without the Sentinel CPS. The primary endpoint of the study is the number of new SBIs or stroke foci detected by diffusion-weighted magnetic resonance imaging (DW MRI). Secondary endpoints include deterioration of cognitive function, development of dementia syndrome, and occurrence of depressive disorders. These endpoints will be assessed using questionnaire tools such as the Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT), Controlled Oral Word Association Test (COWAT), and Hospital Anxiety and Depression Scale (HADS). The observational period for patients in the study is 2 years. Discussion: If the study demonstrates a favorable outcome with reduced incidence of SBI and improved cognitive and mood outcomes in patients receiving cerebral protection devices during LAAC, it will have significant implications for clinical management standards. This would support the use of neuroprotection devices not only for LAAC but also in procedures such as atrial fibrillation ablation or transcatheter mitral valve interventions, where the risk of embolic events and subsequent brain injury may also be present. Trial registration: NCT05369195, registration date 11.05.2022
No takes yet. Share an insight, caveat, or question.
Streb et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: